There might be a potential drug interaction between the two medicines if co-administered due to the presence of dolutegravir active substance in both drugs. Prior to using this combination, it’s necessary to consult with a medical specialist first for proper drug prescription as well as health assessment.
Tivicay is an antiretroviral INSTI drug with an active substance dolutegravir. It’s approved for use in HIV treatment in combination with other ARVs. It’s a highly potent med taken orally and highly effective in all patients who have never taken an integrase inhibitor previously [1].
Triumeq is a single-dose drug combination of three active substances: abacavir, dolutegravir, and lamivudine. It’s primarily approved for treatment-naïve individuals in combating HIV/AIDS.
This medicine has high potency with a relatively robust barrier to resistance and is associated with few drug interactions. This medicine is beneficial to individuals with renal problems due to the unavailability of tenofovir DF [2].
These drugs are safe and can be coadministered as there is very low evidence on possible interactions. In clinical tests, the dolutegravir dose (50 mg) in Triumeq is insignificant when combined with some medicines that may lower dolutegravir concentrations.
In the European product label, Triumeq is not recommended for using in conjunction with Tivicay and related medications. However, the US product label for Triumeq recommends an additional 12 hours of separation from this med if an extra dose of dolutegravir (a 50 mg pill) is required.
Nonetheless, it’s advisable not to coadminister Triumeq with any other drug having dolutegravir, lamivudine, or abacavir. If it is required, patient health analysis and a doctor’s prescription are needed when coadministering such drugs [3].